Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...

Popular weight-loss drugs like Wegovy and Zepbound are boosting the use of healthcare in the U.S., leading to an uptick in ...

The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

ResMed has established itself as a key player in the sleep and respiratory care market, with a primary focus on devices for sleep apnea and other respiratory conditions. The company's consistent ...

ResMed Inc. (RMD), based in San Diego ... to enhancing the quality of life for individuals suffering from sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory ailments ...

Various medical devices are available to help treat sleep apnea. Choosing the right one comes down to the severity of your condition, your personal preferences, and your lifestyle. Sleep apnea is ...

The sleep screening devices market is projected to grow from US$ 9,298 million in 2023 to US$ 17,564.5 million by 2033, at a ...

ResMed's Chief Medical Officer has suggested doctors will prescribe using both drugs and devices such as his company makes together to help sleep apnea suffers. Shares of ResMed (RMD) and Inspire ...